Add listing
    0
    Add listing

    Adoram Therapeutics SA Verified listing

    • Swiss Biotech Association
      Member

    Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).

    Location
    Additional address info
    • c/o Hesham Hamid
    Canton
    Facts & figures
    • Type of organization
      Private company
    • Year of foundation
      2022
    • Number of employees in Switzerland
      1-9
    Key business

    You may also be interested in